questionText: To ask the Secretary of State for Health and Social Care, what discussions he has had with NICE on its decision not to recommend the use of donanemab and lecanemab for Alzheimer's patients by the NHS.
answerText: Department officials regularly discuss a range of issues with colleagues in the National Institute for Health and Care Excellence (NICE), including the progress of specific appraisals. NICE develops its guidance independently in line with its established ...
heading: Alzheimer's Disease: Donanemab and Lecanemab